Measurable (formerly minimal) residual disease (MRD) assessment by flow cytometry is a powerful prognostic tool and becoming part of standard patient management for a number of hematologic malignancies including chronic lymphocytic leukemia (CLL), multiple myeloma (MM), B-and T-acute lymphocytic leukemia, and acute myeloid leukemia (AML). This has been driven in part by the long lasting remissions of many patients achieved on clinical trials and the need for surrogate endpoints for progression free survival (DiGiuseppe & Wood, 2019;